Literature DB >> 1701416

Inhibition of cholera toxin binding to membrane receptors by pig gastric mucin-derived glycopeptides: differential effect depending on the ABO blood group antigenic determinants.

C G Monferran1, G A Roth, F A Cumar.   

Abstract

The capacity of pig gastric mucin-derived glycopeptides to interfere with the binding of cholera toxin (CT) to membrane receptors was studied. Two types of glycopeptide preparations with or without human blood group A antigenic activity were assayed for comparison in a system in which the target for the toxin was rat erythrocyte ghosts. Blood group A-active glycopeptides (A+ glycopeptides) were more potent inhibitors for the toxin binding than those lacking group A activity (A- glycopeptides). The mean values of the 50% inhibitory dose revealed that the A+ glycopeptide preparations were 6.6-fold-more potent inhibitors than the A- ones (P less than 0.001). The inhibitory capacity of the different A+ glycopeptide preparations was not directly proportional to the group A antigenic titer. The A+ glycopeptides showed a higher capacity than the A- glycopeptides to interact with the toxin as revealed by CT-glycopeptide complex formation, which could be detected by Sephacryl S-400 chromatography. This result suggests that glycopeptide inhibition of CT binding to the erythrocyte ghosts is mediated by a competition between the GM1 receptors and the glycopeptides for the toxin. The differential effect between both types of glycoconjugates was independent of the way of measuring the amount of glycopeptides used (dry weight, carbohydrate or protein content). The existence in the gastrointestinal tract of mucins not carrying or carrying different ABO blood group determinants, which could behave as more or less potent inhibitors of CT binding to membrane receptors, may help to explain the relationship between ABO blood groups and severity of cholera.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701416      PMCID: PMC313763          DOI: 10.1128/iai.58.12.3966-3972.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; S Huda; F Ahmed; J Gomes; M R Rao; A M Svennerholm
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Studies on yeast metabolism. I. Fractionation and microdetermination of cell carbohydrates.

Authors:  W E TREVELYAN; J S HARRISON
Journal:  Biochem J       Date:  1952-01       Impact factor: 3.857

4.  Binding of cholera toxin to pig intestinal mucosa glycosphingolipids: relationship with the ABO blood group system.

Authors:  F R Bennun; G A Roth; C G Monferran; F A Cumar
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

5.  Cholera enterotoxin-induced mucus secretion and increase in the mucus blanket of the rabbit ileum in vivo.

Authors:  G J Leitch
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

6.  Detection of gangliosides that bind cholera toxin: direct binding of 125I-labeled toxin to thin-layer chromatograms.

Authors:  J L Magnani; D F Smith; V Ginsburg
Journal:  Anal Biochem       Date:  1980-12       Impact factor: 3.365

7.  Binding of Vibrio cholera toxin and the heat-labile enterotoxin of Escherichia coli to GM1, derivatives of GM1, and nonlipid oligosaccharide polyvalent ligands.

Authors:  C L Schengrund; N J Ringler
Journal:  J Biol Chem       Date:  1989-08-05       Impact factor: 5.157

8.  Association between O blood group and occurrence and severity of diarrhoea due to Escherichia coli.

Authors:  R E Black; M M Levine; M L Clements; T Hughes; S O'Donnell
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

9.  Antigenic determinants of the cholera/coli family of enterotoxins.

Authors:  R A Finkelstein; M F Burks; A Zupan; W S Dallas; C O Jacob; D S Ludwig
Journal:  Rev Infect Dis       Date:  1987 Sep-Oct

10.  Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb.

Authors:  S Fukuta; J L Magnani; E M Twiddy; R K Holmes; V Ginsburg
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

View more
  11 in total

1.  Fucosylation and protein glycosylation create functional receptors for cholera toxin.

Authors:  Amberlyn M Wands; Akiko Fujita; Janet E McCombs; Jakob Cervin; Benjamin Dedic; Andrea C Rodriguez; Nicole Nischan; Michelle R Bond; Marcel Mettlen; David C Trudgian; Andrew Lemoff; Marianne Quiding-Järbrink; Bengt Gustavsson; Catharina Steentoft; Henrik Clausen; Hamid Mirzaei; Susann Teneberg; Ulf Yrlid; Jennifer J Kohler
Journal:  Elife       Date:  2015-10-29       Impact factor: 8.140

2.  Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity.

Authors:  Jason B Harris; Ashraful I Khan; Regina C LaRocque; David J Dorer; Fahima Chowdhury; Abu S G Faruque; David A Sack; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  Fucosylated Molecules Competitively Interfere with Cholera Toxin Binding to Host Cells.

Authors:  Amberlyn M Wands; Jakob Cervin; He Huang; Ye Zhang; Gyusaang Youn; Chad A Brautigam; Maria Matson Dzebo; Per Björklund; Ville Wallenius; Danielle K Bright; Clay S Bennett; Pernilla Wittung-Stafshede; Nicole S Sampson; Ulf Yrlid; Jennifer J Kohler
Journal:  ACS Infect Dis       Date:  2018-02-22       Impact factor: 5.084

4.  Interaction of cholera toxin and Escherichia coli heat-labile enterotoxin with glycoconjugates from rabbit intestinal brush border membranes: relationship with ABH blood group determinants.

Authors:  L E Balanzino; J L Barra; E M Galván; G A Roth; C G Monferran
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

5.  Towards a structural basis for the relationship between blood group and the severity of El Tor cholera.

Authors:  Pintu K Mandal; Thomas R Branson; Edward D Hayes; James F Ross; Jose A Gavín; Antonio H Daranas; W Bruce Turnbull
Journal:  Angew Chem Int Ed Engl       Date:  2012-04-05       Impact factor: 15.336

6.  GM1 ganglioside-independent intoxication by Cholera toxin.

Authors:  Jakob Cervin; Amberlyn M Wands; Anna Casselbrant; Han Wu; Soumya Krishnamurthy; Aleksander Cvjetkovic; Johanna Estelius; Benjamin Dedic; Anirudh Sethi; Kerri-Lee Wallom; Rebecca Riise; Malin Bäckström; Ville Wallenius; Frances M Platt; Michael Lebens; Susann Teneberg; Lars Fändriks; Jennifer J Kohler; Ulf Yrlid
Journal:  PLoS Pathog       Date:  2018-02-12       Impact factor: 6.823

Review 7.  The role of PS 18:0/18:1 in membrane function.

Authors:  Tore Skotland; Kirsten Sandvig
Journal:  Nat Commun       Date:  2019-06-21       Impact factor: 14.919

8.  Escherichia coli heat-labile enterotoxin preferentially interacts with blood group A-active glycolipids from pig intestinal mucosa and A- and B-active glycolipids from human red cells compared to H-active glycolipids.

Authors:  J L Barra; C G Monferran; L E Balanzino; F A Cumar
Journal:  Mol Cell Biochem       Date:  1992-09-22       Impact factor: 3.396

9.  Stereochemical Control Yields Mucin Mimetic Polymers.

Authors:  Austin G Kruger; Spencer D Brucks; Tao Yan; Gerardo Cárcarmo-Oyarce; Yuan Wei; Deborah H Wen; Dayanne R Carvalho; Michael J A Hore; Katharina Ribbeck; Richard R Schrock; Laura L Kiessling
Journal:  ACS Cent Sci       Date:  2021-03-30       Impact factor: 14.553

10.  Differential interaction of Escherichia coli heat-labile toxin and cholera toxin with pig intestinal brush border glycoproteins depending on their ABH and related blood group antigenic determinants.

Authors:  L E Balanzino; J L Barra; C G Monferran; F A Cumar
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.